NCT00558051

Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer

Phase I Evaluation of Semi-continuous Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Sponsor: Pawel Kalisnki, Universiy of Pittsburgh
Phase 1

Relates to JIC Article April 2016

NCT02334735

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

A Phase II Open Label, Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence

Condition: Melanoma
Sponsor: Nina Bhardwaj
Collaborators: New York Univ School of Medicine, MEmorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, Melanoma Research Alliance, Oncovir, Inc. 

NCT01456104

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

Conditions: Melanoma
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase 1

NCT01245673

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

Conditions: Multiple Myeloma
Sponsors: Abramson Cancer Center of the University of Pennsylvania
Phase: II 

NCT01189383

IL15 Dendritic Cell Vaccine for Patients With Resected Stage IIIc and Stage IV Melanoma

Conditions: Stage IIIc/IV Melanoma
Sponsors: Baylor Research Institute
Phase I, II

NCT01171729

Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer

Conditions: Prostatic Cancer
Sponsors: Samsung Medical Center
Phase I, II

NCT01241682

Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

Conditions: Malignant Pleural Mesothelioma
Sponsors: Erasmus Medical Center
Phase I

NCT01082198

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

Conditions: Melanoma (Skin)
Sponsors: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Warsaw, Poland
Phase I, II

NCT00988312

Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

Conditions: Multiple Myeloma, Plasmocytoma
Sponsors: University Hospital Carl Gustav Carus
Phase I

NCT00923910

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Conditions: Acute Myelogenous (AML), Acute Lymphocytic (ALL), Chronic Myelogenous (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL)
Sponsors: National Cancer Institute (NCI)
Phase I, II